**Core Concept**
Bicalutamide is a non-steroidal anti-androgen primarily used in the treatment of prostate cancer. It acts by competitively inhibiting the binding of androgens to androgen receptors, thereby reducing the growth-promoting effects of androgens on prostate cancer cells.

**Why the Correct Answer is Right**
Bicalutamide specifically targets the androgen receptor, which plays a crucial role in the development and progression of prostate cancer. By blocking the androgen receptor, bicalutamide inhibits the transcription of androgen-dependent genes, ultimately leading to a decrease in prostate cancer cell growth and proliferation. This mechanism of action is distinct from other anti-androgenic agents like flutamide, which has a shorter half-life and requires more frequent dosing.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect as it does not accurately describe the primary mechanism of action of bicalutamide.
**Option B:** This option is incorrect as it is not a recognized side effect of bicalutamide.
**Option C:** This option is incorrect as it is not a characteristic of bicalutamide.

**Clinical Pearl / High-Yield Fact**
Bicalutamide is often used in combination with luteinizing hormone-releasing hormone (LHRH) agonists to achieve maximum androgen blockade in the treatment of advanced prostate cancer.

**Correct Answer: B. Bicalutamide is a non-steroidal anti-androgen used to treat prostate cancer by competitively inhibiting androgen receptors.**